Komori
HONYAKU Center (2483) · RiskFirst stated

Revenue decline in the pharmaceutical sector due to fewer inspections of pharmaceutical companies

First written in FY2020-Q3. . Latest entry: FY2020-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Revenue decline in the pharmaceutical sector due to fewer inspections of pharmaceutical companiesA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3First statedAnnual report

    「In the pharmaceutical business, orders remained firm, but revenue decreased 5.5% year on year to ¥2,027 million due to the impact of fewer inspections conducted during the current fiscal year by pharmaceutical companies, the principal customers.」

    Fewer inspections conducted by pharmaceutical companies during the current fiscal year actually occurred as a factor behind the decline in pharmaceutical business revenue, which decreased 5.5% year on year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for HONYAKU Center yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Revenue decline in the pharmaceutical sector due to fewer inspections of pharmaceutical companies | HONYAKU Center Inc. (2483) | Komori